Completed PHASE3 INTERVENTIONAL 1-arm NCT00198484

Evaluation of Vitrase as a Spreading Agent

Evaluation of Vitrase (Hyaluronidase for Injection) Ovine, 200 USP Units/mL, as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs Prior to Ocular Surgery

Sponsor: Bausch & Lomb Incorporated

Conditions Pain

Interventions Vitrase

Updated 7 times since 2017 Last updated: Mar 13, 2013 Started: Oct 31, 2004 Primary completion: Dec 31, 2004 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pain, this trial is completed. The trial is conducted by Bausch & Lomb Incorporated and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated

Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Boston, United States , Edgewood, United States , Fort Oglethorpe, United States , Fort Sam Houston, United States , Galveston, United States , Great Bend, United States , Houston, United States , Kansas City, United States , Littleton, United States and 8 more locations